“The Familial Chylomicronemia Syndrome Market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2034). Furthermore, launching various multiple- Familial Chylomicronemia Syndrome pipeline products will significantly revolutionize the Familial Chylomicronemia Syndrome market dynamics”

 

The Familial Chylomicronemia Syndrome market report provides current treatment practices, Familial Chylomicronemia Syndrome emerging drugs, market share of individual therapies, and current and forecasted 7MM Familial Chylomicronemia Syndrome market size from 2020 to 2034. The report also covers current Familial Chylomicronemia Syndrome treatment market algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

 

Key Takeaways from the Familial Chylomicronemia Syndrome Market Research Report

• The expected launch of therapies and better diagnosis will lead to market growth during the forecast period (2023-2034).
• According to DelveInsight analysis, majority of the cases were accounted by 0-17 years in 2022, in the 7MM.
• As per DelveInsight’s analysis, Familial Chylomicronemia Syndrome Diagnosed Prevalent Cases based on age were categorized into two age-groups, 0–17 years and ≥18 years.
• The leading Familial Chylomicronemia Syndrome Companies working in the market include Ionis Pharmaceuticals Inc., Akcea Therapeutics, Novartis Pharmaceuticals, Arrowhead Pharmaceuticals, UniQure Biopharma B.V., and others.
• Promising Familial Chylomicronemia Syndrome Pipeline Therapies in the various stages of development include ARO-APOC3, sterile normal saline (0.9% NaCl), LCQ908, Olezarsen, Volanesorsen, AKCEA-ANGPTL3-LRx, and others.
• December 2023: Ionis Pharmaceuticals announced a study of Phase 3 clinical trials for Olezarsen. The purpose of this study is to evaluate the effect of olezarsen (formerly known as AKCEA-APOCIII-LRx) on the percent change in fasting triglycerides (TG) from baseline.

 

Discover more about therapies set to grab major Familial Chylomicronemia Syndrome Market Share @ Familial Chylomicronemia Syndrome Market Size

 

Familial Chylomicronemia Syndrome Overview

Familial Chylomicronemia Syndrome (FCS) is a rare genetic lipid disorder, which is characterized by the increase in the levels of triglycerides (TGs) due to mutation in the LPL gene. Disease-causing variants in five other genes namely, APOA5, APOC2, GPD1, GPIHPB1, and LMF1 may also result in Familial Chylomicronemia Syndrome.

 

Familial Chylomicronemia Syndrome Epidemiology Segmentation in the 7MM

• Total Familial Chylomicronemia Syndrome Diagnosed Prevalent Cases
• Familial Chylomicronemia Syndrome Age-specific Diagnosed Prevalent Cases

 

Download the report to understand which factors are driving Familial Chylomicronemia Syndrome Epidemiology Trends @ Familial Chylomicronemia Syndrome Epidemiological Insights

 

Familial Chylomicronemia Syndrome Market Insights

There are several compounds in the development pipeline primarily focusing on improving the LPL-mediated clearance of TGRL by reducing the activity of proteins such as apolipoprotein C-III and ANGPTL 3/4 that block LPL. Although, despite the emerging drugs, there is still a major requirement to recognize the unmet need for effective Familial Chylomicronemia Syndrome treatment options that reduce symptoms and cure the disease.

 

Familial Chylomicronemia Syndrome Market Size

According to DelveInsight analysis, the United States accounted for total market size of USD 2 million of FCS in year 2022 in the 7MM. The market size of the 7MM is anticipated to increase during the forecast period due to the expected launch of emerging therapies.

 

To know more about Familial Chylomicronemia Syndrome Treatment options, visit @ Familial Chylomicronemia Syndrome Drugs

 

Familial Chylomicronemia Syndrome Companies and Therapies

• Ionis Pharmaceuticals Inc.: Olezarsen
• Akcea Therapeutics: AKCEA-ANGPTL3-LRx
• Novartis Pharmaceuticals: LCQ908

 

Familial Chylomicronemia Syndrome Drugs Uptake

Olezarsen, formerly known as IONIS-APOCIII-LRx and AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of Apoc-III in the liver. It is being investigated in Phase III for FCS patients. The drug has also been granted with FTD by the US FDA.

ARO-APOC3 is designed to reduce the production of Apolipoprotein C-III (Apoc-III), a component of triglyceride-rich lipoproteins (TRLs) including VLDL and chylomicrons, and is a key regulator of triglyceride metabolism. Arrowhead clinical trials for ARO-APOC3 have advanced into Phase III. The US FDA has grant orphan drug designation to ARO-APOC3 for FCS treatment.

 

Learn more about the Familial Chylomicronemia Syndrome Pipeline Therapies in clinical trials @ Familial Chylomicronemia Syndrome Market Landscape

 

Scope of the Familial Chylomicronemia Syndrome Market Report

• Coverage- 7MM
• Familial Chylomicronemia Syndrome Companies- Ionis Pharmaceuticals Inc., Akcea Therapeutics, Novartis Pharmaceuticals, Arrowhead Pharmaceuticals, UniQure Biopharma B.V., and others.
• Familial Chylomicronemia Syndrome Pipeline Therapies in the various stages of development include ARO-APOC3, sterile normal saline (0.9% NaCl), LCQ908, Olezarsen, Volanesorsen, AKCEA-ANGPTL3-LRx, and others.
• Familial Chylomicronemia Syndrome Market Dynamics: Familial Chylomicronemia Syndrome Market Drivers and Barriers
• Familial Chylomicronemia Syndrome Market Access and Reimbursement, Unmet Needs, and Future Perspectives

 

Discover more about Familial Chylomicronemia Syndrome Drugs in development @ Familial Chylomicronemia Syndrome Ongoing Clinical Trials Analysis

 

Table of Content

1. Key Insights

2. Familial Chylomicronemia Syndrome Market Report Introduction

3. Familial Chylomicronemia Syndrome Market Overview at a Glance

4. Familial Chylomicronemia Syndrome Epidemiology and Market Methodology

5. Executive Summary of Familial Chylomicronemia Syndrome

6. Key Events

7. Disease Background and Overview Familial Chylomicronemia Syndrome

8. Familial Chylomicronemia Syndrome Epidemiology and Patient Population

9. Familial Chylomicronemia Syndrome Patient Journey

10. Familial Chylomicronemia Syndrome Marketed Drugs

11. Familial Chylomicronemia Syndrome Emerging Drugs

12. Familial Chylomicronemia Syndrome: The 7MM Analysis

13. Familial Chylomicronemia Syndrome SWOT

14. Familial Chylomicronemia Syndrome Unmet Needs

15. Key Opinion Leaders’ Views

16. Familial Chylomicronemia Syndrome Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/stem-cell-market